Hemostemix
Blackfalds
About Hemostemix
Hemostemix a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as bone cell precursors, myocardial cell precursors, and neural cell precursors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: cve:HEM
- Website: hemostemix.com
- Phone: +1 403 471 6665
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/hemostemix-7950 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.